- Home
- FENC vs MNPR Comparison
FENC vs MNPR Comparison
Compare FENC & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- MNPR
- Stock Information
- Founded
- FENC 1996
- MNPR 2014
- Country
- FENC United States
- MNPR United States
- Employees
- FENC N/A
- MNPR N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- MNPR Health Care
- Exchange
- FENC Nasdaq
- MNPR Nasdaq
- Market Cap
- FENC 225.4M
- MNPR 248.8M
- IPO Year
- FENC 2001
- MNPR 2019
- Fundamental
- Price
- FENC $9.05
- MNPR $42.18
- Analyst Decision
- FENC Strong Buy
- MNPR Strong Buy
- Analyst Count
- FENC 2
- MNPR 10
- Target Price
- FENC $13.50
- MNPR $66.56
- AVG Volume (30 Days)
- FENC 67.3K
- MNPR 38.8K
- Earning Date
- FENC 11-06-2025
- MNPR 11-07-2025
- Dividend Yield
- FENC N/A
- MNPR N/A
- EPS Growth
- FENC N/A
- MNPR N/A
- EPS
- FENC N/A
- MNPR N/A
- Revenue
- FENC $33,302,000.00
- MNPR N/A
- Revenue This Year
- FENC $0.96
- MNPR N/A
- Revenue Next Year
- FENC $51.71
- MNPR N/A
- P/E Ratio
- FENC N/A
- MNPR N/A
- Revenue Growth
- FENC N/A
- MNPR N/A
- 52 Week Low
- FENC $3.96
- MNPR $2.29
- 52 Week High
- FENC $9.42
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- FENC 58.08
- MNPR 60.37
- Support Level
- FENC $8.73
- MNPR $32.77
- Resistance Level
- FENC $9.29
- MNPR $36.49
- Average True Range (ATR)
- FENC 0.32
- MNPR 2.88
- MACD
- FENC 0.05
- MNPR 1.27
- Stochastic Oscillator
- FENC 86.06
- MNPR 84.97
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.